

## **Peer Review Plan for the Interim Clinical Recommendations for the Use of Injectable Lenacapavir as HIV Preexposure Prophylaxis, 2025**

**Subject:** HIV preexposure prophylaxis (PrEP) clinical guidelines

**Purpose:** To provide updated recommendations and considerations for use of HIV PrEP in the United States for a new medication, lenacapavir. These recommendations are intended to inform the clinical practice of healthcare professionals.

**Type of Dissemination:** Influential Scientific Information

**Timing of Review (including deferrals):** 04/12/2025 to 05/31/2025

**Type of Review (panel, individual or alternative procedure):** Individual

**Opportunities for the Public to Comment (how and when):** None

**Peer Reviewers Provided with Public Comments Before Their Review:** Not applicable

**Anticipated Number of Reviewers:** 3

**Primary Disciplines or Expertise Needed for Review:** Peer reviewers were selected based on expertise on 1) lenacapavir for PrEP research, 2) PrEP clinical care, and 3) guidelines development for this particular topic. Peer reviewers were selected based on training and relevant experience in the fields of infectious diseases, HIV prevention, and HIV PrEP specifically.

**Reviewers Selected by:** CDC/NCHHSTP

**Public Nominations Requested for Review Panel:** No

**Peer reviewers:** Monica Gandhi, MD; Susan Buchbinder, MD; Raphael Landovitz, MD

### **Charge to Peer Reviewers:**

External peer reviewers are asked to objectively review the draft guideline document and supplemental files, provide feedback where indicated to increase usability and clarity, and to assess whether the type and strength of recommendations is appropriate given the methods and evidence that contributed to the recommendation development.

CDC will review all individual comments from the peer reviewers and will then make decisions about updating the guideline based on all comments. A summary of comments and response (without attribution) will be posted for public review.